REFERENCES
1. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters C. ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v31-9.
2. Waller DA, Dawson AG. Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned. Ann Transl Med 2017;5:240.
3. Kindler HL, Ismaila N, Armato SG 3rd, et al. Treatment of malignant pleural mesothelioma: american society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1343-73.
4. NCCN Clinical Practice Guidelines in Oncology. Malignant Pleural Mesothelioma; 2019. Available from: https://www.nccn.org/ [Last accessed on 30 August 2023].
5. Nakas A, Waller D. Predictors of long-term survival following radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 2014;46:380-5; discussion 385.
6. Meyerhoff RR, Yang CF, Speicher PJ, et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res 2015;196:23-32.
9. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014;83:240-5.
10. Takuwa T, Hasegawa S. Current surgical strategies for malignant pleural mesothelioma. Surg Today 2016;46:887-94.
11. Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg 2014;62:516-21.
12. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90.
13. Bovolato P, Casadio C, Billè A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014;9:390-6.
14. Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 2011;12:763-72.
15. Burt BM, Cameron RB, Mollberg NM, et al. Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg 2014;148:30-5.
16. Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683-90.
17. American College of Surgeons. National Cancer Data Base Participant Use Data File (PUF) Data Dictionary. 2004-2014. Available from: https://www.facs.org/media/brilfbgu/puf-2020-data-dictionary.pdf [Last accessed on 15 Sep 2023].
18. Saddoughi SA, Abdelsattar ZM, Blackmon SH. National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study. Ann Thorac Surg 2018;105:432-7.
19. Rosskamp M, Macq G, Nackaerts K, et al. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer 2018;125:258-64.
20. Espinoza-mercado F, Berz D, Borgella JD, Imai TA, Soukiasian HJ. Neoadjuvant versus adjuvant chemotherapy for resectable malignant pleural mesothelioma: an analysis of the National Cancer Database. J Clin Oncol 2018;36:e20556.
21. Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2009;4:1380-8.
22. Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138-45.
23. Belani CP. Adjuvant and neoadjuvant therapy in non-small cell lung cancer. Semin Oncol 2005;32:S9-15.
24. Beckert AK, Huisingh-Scheetz M, Thompson K, et al. Screening for frailty in thoracic surgical patients. Ann Thorac Surg 2017;103:956-61.
25. Tsiouris A, Hammoud ZT, Velanovich V, Hodari A, Borgi J, Rubinfeld I. A modified frailty index to assess morbidity and mortality after lobectomy. J Surg Res 2013;183:40-6.
26. Wahl TS, Graham LA, Hawn MT, et al. Association of the modified frailty index with 30-day surgical readmission. JAMA Surg 2017;152:749-57.
27. Kojima G, Iliffe S, Walters K. Frailty index as a predictor of mortality: a systematic review and meta-analysis. Age Ageing 2018;47:193-200.
28. Pleurectomy/Decortication (P/D) preceded or followed by chemotherapy in patients with early stage MPM. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02436733 [Last accessed on 30 August 2023].
29. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86.
30. Lim E, Darlison L, Edwards J, et al. Mesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020;10:e038892.
